上海复宏汉霖生物技术股份有限公司药品申请临床试验默示许可获受理

金融界
14 Mar

3月14日,据CDE官网消息,上海复宏汉霖生物技术股份有限公司、上海复宏汉霖生物医药有限公司联合申请药品“重组抗CD38全人单克隆抗体注射液”,获得临床试验默示许可,受理号CXSB2400172。公示信息显示,药品“重组抗CD38全人单克隆抗体注射液”适应症:多发性骨髓瘤。上海复宏汉霖生物技术股份有限公司,成立于2010年,位于上海市,是一家以从事研究和试验发展为主的企业。企业注册资本...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10